New Arrival China C Diff Vancomycin Treatment - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex
New Arrival China C Diff Vancomycin Treatment - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex Detail:
Product Detail
|
NO. |
Products |
CAS No. |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
SI * |
Max * |
Moisture |
||||
|
1 |
Fmoc-Lys(Mtt)-OH | 167393-62-6 | Lysine side chain modification |
≥99.0% |
≤0.1% |
≤0.2% |
≤0.3% |
≤1.0% |
|
2 |
Fmoc-Lys(Alloc)-OH | 146982-27-6 | Lysine side chain modification |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
3 |
Fmoc-Lys(ivDde)-OH | 150629-67-7 | Lysine side chain modification |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Fmoc-Lys(Mmt)-OH | 159857-60-0 | Lysine side chain modification |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
5 |
Fmoc-Glu-OtBu | 84793-07-7 | LiraglutideSemaglutide |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
6 |
Glu-OtBu | 45120-30-7 | LiraglutideSemaglutide |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
7 |
Octadecanedioic acid | 871-70-5 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
8 |
Octadecanedioic acid mono-tert-butyl ester | 843666-40-0 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
9 |
tBu-OOC-C16-CO-Glu-OtBu | 1188328-39-3 | SemaglutideFragment A |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
10 |
AEEA | 134978-97-5 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
11 |
AEEA-OH.HCl | 134979-01-4 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
12 |
Fmoc-AEEA-OH | 166108-71-0 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
13 |
Boc-AEEA-OH | 108466-89-3 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
14 |
AEEA-AEEA | 1143516-05-5 | Semaglutide |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
15 |
Fmoc-AEEA-AEEA-OH | 560088-89-3 | SemaglutideFragment B |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
16 |
Octa(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH | 1118767-16-0 | SemaglutideFragment C |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
17 |
tBu-OOC-C16-CO-Glu(AEEA-AEEA-NHS)-OtBu | 1118767-15-9 | SemaglutideFragment D |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
18 |
Fmoc-Lys(tBu-OOC-C16-CO-Glu(AEEA-AEEA)-OtBu)-OH | 1662688-20-1 | Semaglutide Fragment E |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
19 |
Boc-His(Trt)-OH | 32926-43-5 | The end is histidine |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤4.0% |
|
20 |
Fmoc-Aib-OH | 94744-50-0 | Semaglutide |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
21 |
Boc-His(Trt)-Aib-OH | 2061897-68-3 | Semaglutide |
≥99.0% |
≤0.1% |
≤0.2% |
≤0.3% |
≤2.0% |
|
22 |
Fmoc-Glu(OtBu)-Gly-OH | 866044-63-5 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
23 |
Boc-His(Trt)-Aib-Glu(OtBu)-Gly-OH | 1169630-31-2？ | Semaglutide Fragment F |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
24 |
Boc-His(Trt)-Aib-Glu(OtBu)-Gly-NHS | 1169630-40-3 | Semaglutide Fragment G |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
25 |
Fmoc-Arg(pbf)-Gly-OH | 660846-80-0 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Ala-Ala-OH | 87512-31-0 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
27 |
Fmoc-Thr(tBu)-Phe-OH | 1260609-75-3 ? | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
28 |
Palmitic acid | 1957/10/3 | Liraglutide Fragment 1 |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
29 |
Palm-Glu-OtBu | NA | Liraglutide Fragment 2 |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
30 |
Palm-Glu(NES)-OtBu | NA | Liraglutide Fragment 3 |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
31 |
Fmoc-Lys(Palm-Glu-OtBu)-OH | 1491158-62-3 | Liraglutide |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
32 |
Hexadecanedioic acid | 505-54-4 | Insulin degludec |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
33 |
Hexadecanedioic acid mono-tert-butyl ester | 843666-27-3 | Insulin degludec |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
34 |
tBu-OOC-C14-CO-Glu-OtBu | NA | Insulin degludec Fragment I |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
35 |
tBu-OOC-C14-CO-Glu(NES)-OtBu | NA | Insulin degludec Fragment II |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
SI *= Specific Impurity
Max*= Max Unknown Impurity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
Sanitization
Sanitization of distribution system, including loop and storage tank is performed by Pasteurization. When Pasteurization sanitization is performed, the purified water in tank is heated up to 80°C and start to circulate by distribution system. The sanitization lasts 1 hour after reaching 80°C. Sanitization is performed every quarter. The purified water system sanitization logbook was checked with no excursion highlighted.
Product detail pictures:
Related Product Guide:
We now have several exceptional workers customers good at marketing, QC, and working with types of troublesome trouble during the creation system for New Arrival China C Diff Vancomycin Treatment - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex , The product will supply to all over the world, such as: New Zealand, Cyprus, Japan, Our company warmly invites domestic and overseas customers to come and negotiate business with us. Let us join hands to create a brilliant tomorrow! We are looking forward to cooperating with you sincerely to achieve a win-win situation. We promise to try our best to provide you with high quality and efficient services.
By Salome from Russia - 2018.12.10 19:03
The company has rich resources, advanced machinery, experienced workers and excellent services, hope you keep improving and perfecting your products and service, wish you better!
By Muriel from Korea - 2017.06.22 12:49
